The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab
Authors:
- Christine V. MadsenCMChristine V. Madsen
- Christian DehlendorffCDChristian Dehlendorff
- Anders JakobsenAnders Jakobsen
- Julia S. JohansenJJJulia S. Johansen
- Karina D. SteffensenKSKarina D. Steffensen
- 1 October 2016
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 26 (8) , 1390-1398
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Unveiling YKL-40, from Serum Marker to Target Therapy in GlioblastomaFrontiers in Oncology, 2014
- Chitinase 3-like 1 Regulates Cellular and Tissue Responses via IL-13 Receptor α2Cell Reports, 2013
- YKL-40 acts as an angiogenic factor to promote tumor angiogenesisFrontiers in Physiology, 2013
- YKL-40 Is Differentially Expressed in Human Embryonic Stem Cells and in Cell Progeny of the Three Germ LayersJournal of Histochemistry & Cytochemistry, 2011
- A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in CancersMolecular Cancer Therapeutics, 2011
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of GlioblastomaJournal of Biological Chemistry, 2011
- Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and InjuryAnnual Review of Physiology, 2011
- YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Cancers, 2010
- Experimental anti‐angiogenesis causes upregulation of genes associated with poor survival in glioblastomaInternational Journal of Cancer, 2007
- YKL-40 Protein Expression in the Early Developing Human Musculoskeletal SystemJournal of Histochemistry & Cytochemistry, 2007